A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 568 to 566
  2. Study sites: 566 to 568
    • Eligibility criteria expanded, about 4 words
  3. Study sites: 567 to 566v16
  4. Site details revised at 12 of 567 sitesv15
  5. Study sites: 568 to 567v14
Show 12 earlier versionsHide 12 earlier versions
  1. Study sites revised (568)v13
  2. Study sites revised (568)v12
  3. Site details revised at 37 of 568 sitesv11
  4. Site details revised at 50 of 568 sitesv10
  5. Site details revised at 96 of 568 sitesv9
  6. Site details revised at 19 of 568 sitesv8
  7. Study sites: 567 to 568v7
  8. Study sites: 565 to 567v6
  9. Site details revised at 7 of 565 sitesv5
  10. Study sites: 561 to 565v4
  11. Study sites: 559 to 561v3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 525 to 559
    • Start date changed from estimate of Jan 2026 to Dec 1, 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
Heart Disease
8,870 trials monitored
See 440 trials at risk
Stroke
3,560 trials monitored
See 169 trials at risk
Chronic Kidney Disease
1,436 trials monitored
See 75 trials at risk
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Trial Details
NCT Number NCT07241390
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Related terms Heart Diseases, Kidney Diseases, Renal Insufficiency, Chronic, Stroke
Enrollment 7,140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov